The magnitude of upregulation of eotaxin-1 was greater than that of eotaxin-2; blood concentrations of eotaxin-1 and eotaxin-2 were elevated 2.1- and 1.4-fold after 52 weeks of treatment with benralizumab in the asthma cohort and 2.3- and 1.7-fold after 32 weeks of treatment with benralizumab in the COPD cohort. This evidence concerns the gene CCL24 and asthma.